Pfizer / Hospira: Through the lookingglass: assessing competition by biosimilars* In a nutshell In Pfizer/Hospira, the Commission assessed biosimilar drugs in detail for the first time. Biosimilars aim to have the same therapeutic mechanism as, and be clinically equivalent to, original patented biological pharmaceuticals. In this case, the Commission found the originator and its biosimilars to be part of the same market. However, the investigation highlighted that competitive dynamics for biosimilars differ from those for generic pharmaceuticals, in particular because of the biosimilar's reduced substitutability with the originator. Due to switching barriers, biosimilars do not only compete on price but also through product differentiation. The merger might have led the merged entity
Share on
|
|
The EU Commission clears acquisition of a pharmaceutical company, with effects in the market for biosimilars, subject to remedies that ensure innovation competition (Pfizer / Hospira)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
